	US 12,338,289 B2
	Antibody variant combinations and uses thereof
Rob De Jong, Utrecht (NL); Frank Beurskens, Utrecht (NL); Simone Oostindie, Utrecht (NL); Aran Frank Labrijn, Nigtevecht (NL); Kristin Strumane, Werkhoven (NL); Janine Schuurman, Diemen (NL); and Bart-Jan De Kreuk, Utrecht (NL)
Assigned to GENMAB B.V., Utrecht (NL)
Appl. No. 17/051,205
Filed by GENMAB B.V., Utrecht (NL)
PCT Filed May 3, 2019, PCT No. PCT/EP2019/061455 § 371(c)(1), (2) Date Oct. 28, 2020, PCT Pub. No. WO2019/211472, PCT Pub. Date Nov. 7, 2019.
Claims priority of application No. PA 2018 00195 (DK), filed on May 3, 2018; and application No. PA 2018 00644 (DK), filed on Sep. 26, 2018.
Prior Publication US 2021/0238296 A1, Aug. 5, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2878 (2013.01) [A61K 45/06 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/2833 (2013.01); C07K 16/2887 (2013.01); C07K 16/2893 (2013.01); C07K 16/2896 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)]

17 Claims

1. A method for treating a disease or disorder, the method comprising administering to a subject in need thereof a first antibody comprising a first Fc region of a human IgG and a first antigen-binding region capable of binding to a first antigen, and a second antibody comprising a second Fc region of a human IgG and a second antigen-binding region capable of binding to a second antigen, wherein the first Fc region comprises G236R, E345R, and K439E substitutions and the second Fc region comprises G237A, E345R, and S440K substitutions, and

wherein the amino acid positions correspond to human IgG1 according to Eu numbering system.